Case number 1:23-cv-00607
AbbVie Inc. v. Prinston Pharmaceutical Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 20, 2024 | 15 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (Attachments: # 1 Stipulation of Dismissal)(ceg) (Entered: 06/20/2024) (0) |
| Aug 16, 2023 | 14 | SO ORDERED Granting (D.I. 12 in 23-cv-374-RGA; D.I. 13 in 23-cv-607-RGA; D.I. 6 in 23-cv-750-RGA; D.I. 12 in 23-cv-448-RGA; D.I. 9 in 23-cv-684-RGA; D.I. 113 in 22-cv-1423-RGA-JLH; D.I. 13 in 23-cv-00470-RGA) Stipulation and Proposed Order Concerning Amended Complaint and Consolidation (see Order for further details). Signed by Judge Richard G. Andrews on 8/16/2023. Associated Cases: 1:22-cv-01423-RGA-JLH et al.(nms) (Entered: 08/16/2023) (7) |
| Aug 10, 2023 | 13 | STIPULATION and Proposed Order Concerning Amended Complaint and Consolidation, AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibits A-G, # 3 Supplemental ANDA form, # 4 Supplemental ANDA form, # 5 Supplemental ANDA form, # 6 Amended Patent Report, # 7 Exhibit 2)(Tigan, Jeremy) Modified on 8/10/2023 (nms). (Entered: 08/10/2023) (0) |
| Aug 9, 2023 | 12 | MOTION for Pro Hac Vice Appearance of Attorney H. Howard Wang and Jason A. Lief - filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Taylor, Daniel) (Entered: 08/09/2023) (4) |
| Aug 2, 2023 | 10 | ANSWER to 1 Complaint and Additional Defenses, by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) Modified on 8/2/2023 (nms). (Entered: 08/02/2023) (30) |
| Aug 2, 2023 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zhejiang Huahai Pharmaceutical Co., Ltd. for Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd. filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Taylor, Daniel) (Entered: 08/02/2023) (1) |
| Jun 16, 2023 | 6 | WAIVER OF SERVICE returned executed by AbbVie Inc.: For Prinston Pharmaceutical Inc. waiver sent on 6/16/2023, answer due 8/15/2023. (Tigan, Jeremy) (Entered: 06/16/2023) (1) |
| Jun 16, 2023 | 7 | WAIVER OF SERVICE returned executed by AbbVie Inc.: For Zhejiang Huahai Pharmaceutical Co., Ltd. waiver sent on 6/16/2023, answer due 8/15/2023. (Tigan, Jeremy) (Entered: 06/16/2023) (1) |
| Jun 16, 2023 | 8 | WAIVER OF SERVICE returned executed by AbbVie Inc.: For Solco Healthcare US, LLC waiver sent on 6/16/2023, answer due 8/15/2023. (Tigan, Jeremy) (Entered: 06/16/2023) (1) |
| Jun 16, 2023 | 9 | Amended Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 24, 2023. Date of Expiration of Patent: No. 11,542,239 on July 23, 2039. Hatch-Waxman Regulatory Exclusivity Deadline: January 23, 2026. (Tigan, Jeremy) (Entered: 06/16/2023) (3) |
| Jun 2, 2023 | 1 | Complaint* (1) |
| Jun 2, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 06/02/2023) (3) |
| Jun 2, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 24, 2023. Date NDA Holder Received Notice: April 24, 2023. Date of Expiration of Patent: July 23, 2039. Hatch-Waxman Regulatory Exclusivity Deadline: January 23, 2026. (twk) (Entered: 06/02/2023) (2) |
| Jun 2, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (twk) (Entered: 06/02/2023) (1) |
| Jun 2, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (twk) (Entered: 06/02/2023) (2) |
